Halyard Health, Inc. (NYSE:HYH) – Analysts at KeyCorp dropped their Q4 2017 earnings per share estimates for Halyard Health in a research note issued to investors on Wednesday. KeyCorp analyst M. Mishan now forecasts that the medical instruments supplier will post earnings per share of $0.49 for the quarter, down from their prior estimate of $0.51.
A number of other equities analysts also recently issued reports on the company. Deutsche Bank AG increased their price target on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research report on Wednesday, July 12th. BidaskClub downgraded Halyard Health from a “buy” rating to a “hold” rating in a research report on Saturday, July 8th. Finally, TheStreet raised Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Halyard Health presently has an average rating of “Buy” and a consensus target price of $42.25.
COPYRIGHT VIOLATION NOTICE: “Q4 2017 EPS Estimates for Halyard Health, Inc. (NYSE:HYH) Cut by KeyCorp” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/08/19/q4-2017-eps-estimates-for-halyard-health-inc-nysehyh-cut-by-keycorp-updated.html.
Shares of Halyard Health (NYSE:HYH) traded up 0.07% during trading on Monday, reaching $42.50. The company’s stock had a trading volume of 14,974 shares. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of 40.87 and a beta of 1.78. The company has a 50-day moving average price of $39.44 and a 200-day moving average price of $38.58. Halyard Health has a one year low of $31.59 and a one year high of $42.54.
Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the consensus estimate of $0.37 by $0.14. The business had revenue of $399.20 million during the quarter, compared to analyst estimates of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The company’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the firm posted $0.45 earnings per share.
Large investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock worth $226,229,000 after buying an additional 5,847,442 shares during the period. Norges Bank bought a new stake in shares of Halyard Health during the fourth quarter worth $17,606,000. Dimensional Fund Advisors LP boosted its stake in shares of Halyard Health by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,625,156 shares of the medical instruments supplier’s stock worth $99,992,000 after buying an additional 415,105 shares during the period. Vanguard Group Inc. boosted its stake in shares of Halyard Health by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock worth $165,711,000 after buying an additional 196,367 shares during the period. Finally, Credit Agricole S A boosted its stake in shares of Halyard Health by 450.0% in the first quarter. Credit Agricole S A now owns 132,000 shares of the medical instruments supplier’s stock worth $5,028,000 after buying an additional 108,000 shares during the period. Hedge funds and other institutional investors own 90.28% of the company’s stock.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
What are top analysts saying about Halyard Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halyard Health Inc. and related companies.